Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia

被引:11
作者
Najarian, Dean [1 ]
Turkoz, Ibrahim [2 ,8 ]
Knight, R. Karl
Galderisi, Silvana [3 ]
Lamaison, Hector F. [4 ]
Zalitacz, Piotr [5 ]
Aravind, Suresh [2 ,7 ]
Richarz, Ute [6 ]
机构
[1] Janssen Sci Affairs LLC, Titusville, NJ USA
[2] Janssen Res & Dev LLC, Titusville, NJ USA
[3] Univ Campania Luigi Vanvitelli, Naples, Italy
[4] Natl Univ La Plata UNLP, Dept Psychiat, Buenos Aires, Argentina
[5] Gorlice Specialist Hosp, Psychiat Unit, Gorlice, Poland
[6] Cilag Int, Janssen Res & Dev, Gubelstr, Zug, Switzerland
[7] Dural Consulting LLC, St Petersburg, FL USA
[8] Janssen Res & Dev LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
关键词
Long-term efficacy; schizophrenia; long-acting injectable; open-label extension; paliperidone palmitate 6-month; ACTING INJECTABLE ANTIPSYCHOTICS; PALMITATE; RELAPSE; REHOSPITALIZATION; NONADHERENCE; MEDICATION; ADHERENCE; PLACEBO;
D O I
10.1093/ijnp/pyad028
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Paliperidone palmitate 6-month (PP6M) demonstrated noninferiority to paliperidone palmitate 3-month in preventing relapse in patients with schizophrenia in a phase 3 double-blind (DB) study (NCT03345342). Here, we report long-term efficacy and safety results from a 2-year single-arm, open-label extension (OLE; NCT04072575) of this DB study. Methods Participants who completed the DB study without relapse were enrolled and followed-up every 3 months up to 2 years. Participants received 4 PP6M gluteal injections (700/1000 mg eq.) at baseline, 6-month, 12-month, and 18-month visits. Efficacy endpoints included assessment of relapse, Positive and Negative Syndrome Scale total score, Personal and Social Performance score, and Clinical Global Impression-Severity scale change from baseline. Safety was assessed by treatment-emergent adverse events (TEAEs), physical examinations, and laboratory tests. Results Of 178 participants enrolled, 154 (86.5%) completed the OLE (mean age: 40.4 years, men: 70.8%; mean duration of PP6M exposure during OLE: 682.1 days). Overall, 7/178 (3.9%) participants relapsed between 20 and 703 days after enrolment. Mean (SD) changes from baseline to endpoint were as follows: Positive and Negative Syndrome Scale total score, 0.7 (8.22); Clinical Global Impression-Severity, 0.0 (0.51); and Personal and Social Performance Scale, 0.5 (7.47). Overall, 111/178 participants (62.4%) reported & GE;1 TEAE; most common (>5%) TEAEs were headache (13.5%) and increased blood prolactin/hyperprolactinemia (18.0%); 8/178 (4.5%) participants experienced serious TEAEs, and 6/178 (3.4%) participants withdrew due to TEAEs. No deaths were reported. Conclusions The relapse rate observed with PP6M during the 2-year OLE was low (3.9%). Clinical and functional improvements demonstrated in the DB study were maintained during OLE, and no new safety concerns were identified.
引用
收藏
页码:537 / 544
页数:8
相关论文
共 50 条
[21]   Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence [J].
Si, Tianmei ;
Li, Nan ;
Lu, Huafei ;
Cai, Shangli ;
Zhuo, Jianmin ;
Correll, Christoph U. ;
Zhang, Lili ;
Feng, Yu .
JOURNAL OF PSYCHOPHARMACOLOGY, 2018, 32 (06) :691-701
[22]   Comparison of Olanzapine Long-Acting Injection and Oral Olanzapine A 2-Year, Randomized, Open-Label Study in Outpatients With Schizophrenia [J].
Detke, Holland C. ;
Weiden, Peter J. ;
Llorca, Pierre-Michel ;
Choukour, Moutaz ;
Watson, Susan B. ;
Brunner, Elizabeth ;
Ascher-Svanum, Haya .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2014, 34 (04) :426-434
[23]   Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study [J].
Giron-Hernandez, Cesar ;
Han, Joong Hee ;
Alberio, Roberta ;
Singh, Arun ;
Garcia-Portilla, Maria Paz ;
Pompili, Maurizio ;
Knight, R. Karl ;
Richarz, Ute ;
Gopal, Srihari ;
Antunes, Jose .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 :895-906
[24]   Asian Subgroup Analysis of the REMISSIO Study: A Long-Term Efficacy and Safety Study of Paliperidone Palmitate 3-month Formulation in Patients with Stable Schizophrenia in a Naturalistic Clinical Setting [J].
Chung, Young-Chul ;
Yang, Yen Kuang ;
Sulaiman, Ahmad Hatim ;
Bergmans, Paul ;
Tan, Wilson .
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2022, 20 (03) :427-439
[25]   Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results [J].
Fleischer, David M. ;
Shreffler, Wayne G. ;
Campbell, Dianne E. ;
Green, Todd D. ;
Anvari, Sara ;
Assa'ad, Amal ;
Begin, Philippe ;
Beyer, Kirsten ;
Bird, J. Andrew ;
Brown-Whitehorn, Terri ;
Byrne, Aideen ;
Chan, Edmond S. ;
Cheema, Amarjit ;
Chinthrajah, Sharon ;
Chong, Hey Jin ;
Davis, Carla M. ;
Ford, Lara S. ;
Gagnon, Remi ;
Greenhawt, Matthew ;
Hourihane, Jonathan O'B ;
Jones, Stacie M. ;
Kim, Edwin H. ;
Lange, Lars ;
Lanser, Bruce J. ;
Leonard, Stephanie ;
Mahler, Vera ;
Maronna, Andreas ;
Nowak-Wegrzyn, Anna ;
Oriel, Roxanne C. ;
O'Sullivan, Michael ;
Petroni, Daniel ;
Pongracic, Jacqueline A. ;
Prescott, Susan L. ;
Schneider, Lynda C. ;
Smith, Peter ;
Staab, Doris ;
Sussman, Gordon ;
Wood, Robert ;
Yang, William H. ;
Lambert, Romain ;
Peillon, Aurelie ;
Bois, Timothee ;
Sampson, Hugh A. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 146 (04) :863-874
[26]   Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study [J].
Saito, Takuya ;
Hyodo, Yohei ;
Sakaguchi, Reiko ;
Nakamura, Hiroshi ;
Ishigooka, Jun .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2022, 32 (01) :24-35
[27]   Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study) [J].
Partinen, Markku ;
Hirvonen, Kari ;
Jama, Leni ;
Alakuijala, Anniina ;
Hublin, Christer ;
Tamminen, Ilkka ;
Koester, Juergen ;
Reess, Juergen .
SLEEP MEDICINE, 2008, 9 (05) :537-541
[28]   Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study [J].
Inada, Ken ;
Yamada, Sakiko ;
Akiyoshi, Hisashi ;
Kojima, Yoshitsugu ;
Iwashita, Shuichi ;
Ishigooka, Jun .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 :2267-2275
[29]   Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study [J].
Durgam, Suresh ;
Landbloom, Ronald P. ;
Mackle, Mary ;
Wu, Xiao ;
Mathews, Maju ;
Nasrallah, Henry A. .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 :2021-2035
[30]   Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study [J].
Xenofon Baraliakos ;
Désirée van der Heijde ;
Joachim Sieper ;
Robert D. Inman ;
Hideto Kameda ;
Yihan Li ;
Xianwei Bu ;
Anna Shmagel ;
Peter Wung ;
In-Ho Song ;
Atul Deodhar .
Arthritis Research & Therapy, 25